Chemical Compound

Neomycin C

CAS Registry Number 66-86-4
Back to search Request a Quote
Neomycin C chemical structure
Primary Record

Neomycin C

In stock
5,692 g
Purity
99.3 %
CAS
66-86-4

Compound Identifiers & Properties

CAS
66-86-4
PubChem CID
456194
SMILES
C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CN)O)O)N)O)O)N
Canonical SMILES
NC[C@H]1O[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@H](CN)[C@@H](O)[C@H](O)[C@H]4N)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O

Names & Synonyms

  • Neomycin C
  • Dekamycin II
  • neomycin
  • Framycetin
  • Bykomycin
  • Neomycine
  • Fradiomycin C
  • Neomycin C Hexaacetate
  • AC1L9UFL
  • NEOMYCIN C [MI]
  • RefChem:165307
  • 6B1U1NS16Z
  • UNII-6B1U1NS16Z
  • 66-86-4
  • Neomycin Sulfate EP Impurity C
  • CHEBI:53634
  • DTXSID80892006
  • orb1983331
  • SCHEMBL12126553
  • DTXCID001474264
  • C23H46N6O13
  • BBF-02117
  • CID456194
  • C23-H46-N6-O13
  • J4.457A
  • HY-131130
  • CS-0129179
  • C15652
  • NEOMYCIN SULFATE IMPURITY C [EP IMPURITY]
  • (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
  • Q27124124
  • (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
  • (1R,2R,3S,4R,6S)-4,6-diamino-2-((3-O-(2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-beta-D-ribofuranosyl)oxy)-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
  • (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-2-((2S,3R,4S,5R)-4-((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl)oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl)oxy-3-hydroxycyclohexyl)oxyoxane-3,4-diol
  • (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
  • 1404-04-2
  • 4-O-(2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-5-O-[3-O-(2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-beta-D-ribofuranosyl]-2-deoxy-D-streptamine
  • 5-amino-2-(aminomethyl)-6-[5-[3,5-diamino-2-[3-amino-6-(aminomethyl)-4 ,5-dihydroxy-oxan-2-yl]oxy-6-hydroxy-cyclohexyl]oxy-4-hydroxy-2-(hydro xymethyl)oxolan-3-yl]oxy-oxane-3,4-diol
  • 5-amino-2-(aminomethyl)-6-[5-[3,5-diamino-2-[3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]oxy-6-hydroxy-cyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-oxane-3,4-diol
  • D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->3)-O-.BETA.-D-RIBOFURANOSYL-(1->5)-O-(2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-
  • D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->3)-.BETA.-D-RIBOFURANOSYL-(1->5))-2-DEOXY-
  • D-Streptamine, O-2,6-Diamino-2,6-Dideoxy-Alpha-D-Glucopyranosyl-(1-4)-O-(O-2,6-Diamino-2,6-Dideoxy-Alpha-D-Glucopyranosyl-(1-3)-Beta-D-Ribofuranosyl-(1-5))-2-Deoxy-
  • D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-
  • Framycetin sulfate EP Impurity C; Neomycin sulfate EP Impurity C; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol
  • O-2,6-Diamino-2,6-dideoxy-a-D-glucopyranosyl-(1?3)-O-ss-D-ribofuran osyl-(1?5)-O-[2,6-diamino-2,6-dideoxy-a-D-glucopyranosyl-(1?4)]-2-deoxy-D-streptamine Hexaacetate; Dekamycin II Hexaacetate;